



KNOPP BIOSCIENCES is a drug discovery and development company focused on delivering breakthrough treatments for unmet medical needs through innovation, experience and partnership. Our clinical and preclinical programs focus on novel mechanisms of mitochondrial energetics and our lead compound, dexpramipexole, is currently in Phase 3 clinical development for amyotrophic lateral sclerosis. Additional programs include dexpramipexole combination therapy for Parkinson’s disease and the discovery of ion channel modulators for pain and epilepsy.
Knopp employs innovative approaches to persistent challenges in drug discovery and development. We direct our discovery research toward a novel paradigm of mitochondrial health and dysfunction. Our clinical scientists are noted for innovative study designs and advances in quality. At Knopp, we embrace rigor while resisting dogma.
Knopp is aligned with leading collaborators in drug discovery and development. We have partnered the dexpramipexole development program for ALS with Biogen Idec, a global leader in the development and commercialization of neurology products. Our discovery research, preclinical development, and manufacturing and formulation activities are supported by world-class organizations acting as extensions of the Knopp team.
The Knopp team combines executive experience, operational know-how, and entrepreneurial agility. Former senior executives from Bristol-Myers Squibb and other major biopharma companies are joined here by veterans of technology investing and venture creation.
PITTSBURGH, Pa. (November 21, 2011) -- Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive ......
--Promising New ALS Drug Treatment Enters Phase III of Development-- PITTSBURGH, PA (March 31, 2011) - The ALS Association of ......
San Diego, CA - February 25-29, 2012 Learn more about this event. ...